Tanzina Haque

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo
    Tanzina Haque
    Molecular and Clinical Virology, University of Edinburgh, Summerhall, Edinburgh, United Kingdom
    J Infect Dis 194:584-7. 2006
  2. doi Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases
    Tanzina Haque
    Department of Virology, Royal Free Hospital, UCL Medical School, London, United Kingdom
    J Med Virol 83:311-6. 2011
  3. ncbi Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial
    Tanzina Haque
    Clinical and Molecular Virology Laboratory, University of Edinburgh, Edinburgh, United Kingdom
    Blood 110:1123-31. 2007
  4. ncbi Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases
    Gwen M Wilkie
    Laboratory for Clinical and Molecular Virology, The University of Edinburgh, Summerhall, Edinburgh, United Kingdom
    J Immunother 27:309-16. 2004
  5. doi Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation
    Ben Carpenter
    Department of Haematology, Royal Free Hampstead NHS Trust, London, United Kingdom
    Transplantation 90:564-70. 2010
  6. pmc Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
    Paul D Griffiths
    Centre for Virology, UCL Medical School, London, UK
    Lancet 377:1256-63. 2011
  7. ncbi Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease
    Karen A McAulay
    Clinical and Basic Virology Laboratory, School of Biomedical Sciences, University of Edinburgh, Summerhall, Edinburgh, UK
    J Immunol 182:3892-901. 2009
  8. pmc Cytolytic mechanisms and T-cell receptor Vbeta usage by ex vivo generated Epstein-Barr virus-specific cytotoxic T lymphocytes
    Victoria J Vanhoutte
    Clinical and Molecular Virology, University of Edinburgh, Summerhall, Edinburgh, UK
    Immunology 127:577-86. 2009
  9. doi Immunotherapy and vaccination after transplant: the present, the future
    Vincent C Emery
    Department of Infection, University College London, Rowland Hill Street, Hampstead, London NW3 2QG, UK
    Infect Dis Clin North Am 24:515-29. 2010
  10. doi Prospective monitoring of Epstein-Barr virus DNA in adult renal transplant recipients during the early posttransplant period: role of mycophenolate mofetil
    Michael V Holmes
    Centre for Virology, Royal Free Campus, UCL Medical School, London, United Kingdom
    Transplantation 87:852-6. 2009

Collaborators

Detail Information

Publications16

  1. ncbi A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo
    Tanzina Haque
    Molecular and Clinical Virology, University of Edinburgh, Summerhall, Edinburgh, United Kingdom
    J Infect Dis 194:584-7. 2006
    ..No adverse reactions were seen in the adult or in 3 of the transplant recipients. The remaining patient developed a hypersensitivity reaction, thus underlining the need to humanize the MAb...
  2. doi Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases
    Tanzina Haque
    Department of Virology, Royal Free Hospital, UCL Medical School, London, United Kingdom
    J Med Virol 83:311-6. 2011
    ..In both cases there was a significant correlation between sCD30 and EBV DNA levels in plasma (Pā€‰<ā€‰0.0001). This study demonstrates that sCD30 and EBV DNA levels can be used as potential markers for diagnosis of IM and PTLD...
  3. ncbi Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial
    Tanzina Haque
    Clinical and Molecular Virology Laboratory, University of Edinburgh, Edinburgh, United Kingdom
    Blood 110:1123-31. 2007
    ..Our results show that allogeneic CTLs are a safe and rapid therapy for PTLD, bypassing the need to grow CTLs for individual patients. The response rate in this poor prognosis patient group is encouraging...
  4. ncbi Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases
    Gwen M Wilkie
    Laboratory for Clinical and Molecular Virology, The University of Edinburgh, Summerhall, Edinburgh, United Kingdom
    J Immunother 27:309-16. 2004
    ..Additionally, other patient groups, such as those with EBV-positive Hodgkin disease, may benefit from CTL treatment...
  5. doi Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation
    Ben Carpenter
    Department of Haematology, Royal Free Hampstead NHS Trust, London, United Kingdom
    Transplantation 90:564-70. 2010
    ..The pattern of EBV reactivation in patients receiving allogeneic HSCT, incorporating in vivo or in vitro alemtuzumab as the method of TCD, is not known...
  6. pmc Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
    Paul D Griffiths
    Centre for Virology, UCL Medical School, London, UK
    Lancet 377:1256-63. 2011
    ..Values of viral load correlate with development of end-organ disease and are moderated by pre-existing natural immunity. Our aim was to determine whether vaccine-induced immunity could do likewise...
  7. ncbi Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease
    Karen A McAulay
    Clinical and Basic Virology Laboratory, School of Biomedical Sciences, University of Edinburgh, Summerhall, Edinburgh, UK
    J Immunol 182:3892-901. 2009
    ..These observations should be considered when designing and implementing CTL therapies...
  8. pmc Cytolytic mechanisms and T-cell receptor Vbeta usage by ex vivo generated Epstein-Barr virus-specific cytotoxic T lymphocytes
    Victoria J Vanhoutte
    Clinical and Molecular Virology, University of Edinburgh, Summerhall, Edinburgh, UK
    Immunology 127:577-86. 2009
    ..001). This difference was not observed with Fas ligand or perforin expression. Our results provide insight into the basic characteristics of ex-vivo-generated CTL...
  9. doi Immunotherapy and vaccination after transplant: the present, the future
    Vincent C Emery
    Department of Infection, University College London, Rowland Hill Street, Hampstead, London NW3 2QG, UK
    Infect Dis Clin North Am 24:515-29. 2010
    ..At present, many of these approaches in transplant recipients have focused on infections such as human cytomegalovirus, but the opportunity to use these examples as proof of concept for other infections is discussed...
  10. doi Prospective monitoring of Epstein-Barr virus DNA in adult renal transplant recipients during the early posttransplant period: role of mycophenolate mofetil
    Michael V Holmes
    Centre for Virology, Royal Free Campus, UCL Medical School, London, United Kingdom
    Transplantation 87:852-6. 2009
    ..Epstein-Barr virus (EBV) is associated with posttransplant lymphoproliferative disease. We monitored the incidence of EBV viraemia in adult renal transplant recipients and investigated the association with clinical parameters...
  11. ncbi Interleukin 28B gene polymorphisms and Epstein-Barr virus-associated lymphoproliferative diseases
    Ela Akay
    Department of Virology, Royal Free Hospital, London, UK
    Intervirology 57:112-5. 2014
    ....
  12. pmc Performance of the architect EBV antibody panel for determination of Epstein-Barr virus infection stage in immunocompetent adolescents and young adults with clinical suspicion of infectious mononucleosis
    Alvaro Guerrero-Ramos
    Department of Virology, Royal Free London NHS Foundation Trust, London, United Kingdom
    Clin Vaccine Immunol 21:817-23. 2014
    ..Concomitant testing for CMV is strongly recommended to aid in the interpretation of EBV serological patterns. ..
  13. ncbi Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells
    Tanzina Haque
    Laboratory for Clinical and Molecular Virology, University of Edinburgh, Edinburgh EH9 1QH, UK
    Lancet 360:436-42. 2002
    ..Since tumour growth results from inadequate T-cell control of latent EBV, new immunotherapeutic approaches to treatment are being pioneered...
  14. ncbi Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation
    Robert F Wynn
    Royal Manchester Children s Hospital, University of Manchester, UK
    Lancet Oncol 6:344-6. 2005
  15. ncbi Epstein-Barr virus load correlating with clinical manifestation and treatment response in a patient with angioimmunoblastic T-cell lymphoma
    Manuel Battegay
    Division of Infectious Diseases, Department of Internal Medicine and Research, University Hospital of Basel, Basel, Switzerland
    Antivir Ther 9:453-9. 2004
    ..This case report demonstrates the close association of EBVL and AITL and a beneficial effect of antiviral therapy at an initial stage of disease manifestation...
  16. ncbi Non-myeloablative bone marrow transplantation in an adult with Wiskott-Aldrich syndrome
    Hilary J Longhurst
    Department of Immunopathology, St Bartholomew s Hospital, London, UK
    Br J Haematol 116:497-9. 2002
    ..We describe a non-myeloablative transplant of a 26-year-old man with WAS, undertaken because of severe infections and vasculitis. Partial engraftment and immunorestoration were achieved. The patient is well 1 year post transplantation...